Skip to content
Business
Link copied to clipboard

Cephalon gets EU approval for pain drug

Cephalon Inc., of Frazer, said today that its oral medication to treat breakthrough cancer pain has received European regulatory approval.

Cephalon Inc., of Frazer, said today that its oral medication to treat breakthrough cancer pain has received European regulatory approval.

The medicine is an oral formulation of the pain therapy fentanyl for adult patients who already take an opioid medicine, such as morphine or Percocet, for underlying chronic pain.

The drug, called Effentora in Europe, was approved in the United States in September 2006 under the name Fentora.

Cephalon said that approval by the European regulatory commission means the biopharmaceuticals company can sell the treatment in the 27 states within the European Union. Cephalon shares were up 3 cents to $63.18 in morning trading on the Nasdaq.